British Journal of Nutrition

Systematic review with meta-analysis

Effectiveness and safety of orally administered immunotherapy for food allergies: a systematic review and meta-analysis

Ulugbek Nurmatova1, Graham Devereuxa2, Allison Wortha1, Laura Healya1 and Aziz Sheikha1 c1

a1 Allergy and Respiratory Research Group, Centre for Population Health Sciences, The University of Edinburgh, Medical School, Doorway 3, Teviot Place, Edinburgh EH8 9AG, UK

a2 Department of Child Health, Royal Aberdeen Children's Hospital, University of Aberdeen, Aberdeen AB25 2ZP, UK

Abstract

The aim of using oral and sublingual immunotherapy with food allergies is to enable the safe consumption of foods containing these allergens in patients with food allergies. In the present study, a systematic review of intervention studies was undertaken; this involved the searching of eleven international databases for controlled clinical trials. We identified 1152 potentially relevant papers, from which we selected twenty-two reports of twenty-one eligible trials (i.e. eighteen randomised controlled trials and three controlled clinical trials). The meta-analysis revealed a substantially lower risk of reactions to the relevant food allergen in those receiving orally administered immunotherapy (risk ratios (RR) 0·21, 95 % CI 0·12, 0·38). The meta-analysis of immunological data demonstrated that skin prick test responses to the relevant food allergen significantly decreased with immunotherapy (mean difference − 2·96 mm, 95 % CI − 4·48, − 1·45), while allergen-specific IgG4 levels increased by an average of 19·9 (95 % CI 17·1, 22·6) μg/ml. Sensitivity analyses excluding studies at the highest risk of bias and subgroup analyses in relation to specific food allergens and treatment approaches generated comparable summary estimates of effectiveness and immunological changes. Pooling of the safety data revealed an increased risk of local (i.e. minor oropharyngeal/gastrointestinal) adverse reactions with immunotherapy (RR 1·47, 95 % CI 1·11, 1·95); there was a non-significant increased average risk of systemic adverse reactions with immunotherapy (RR 1·08, 95 % CI 0·97, 1·19). There is strong evidence that orally administered immunotherapy can induce immunomodulatory changes and thereby promote desensitisation to a range of foods. However, given the paucity of evidence on longer-term safety, effectiveness and cost-effectiveness, orally administered immunotherapy should not be used outside experimental conditions presently.

(Received January 03 2013)

(Revised May 15 2013)

(Accepted June 19 2013)

(Online publication August 15 2013)

Key Words:

  • Food allergies;
  • Oral immunotherapy;
  • Sublingual immunotherapy;
  • Systematic reviews;
  • Meta-analyses

Correspondence

c1 Corresponding author: Professor A. Sheikh, fax +44 131 650 9119; email aziz.sheikh@ed.ac.uk

Footnotes

  Abbreviations: OIT, oral immunotherapy; RR, risk ratio; SLIT, sublingual immunotherapy

0Comments